Surgery
Published September 1, 2023 | Version v1
Journal article Open

Impact of мalabsorptive bariatric surgery on liver function and preoperative hepatic steatosis in morbidly obese patient

Authors/Creators

  • 1. University Hospital Center Albacete

Description

A retrospective and prospective study was conducted on preoperative hepatic steatosis and postoperative liver function in 141 morbidly obese patients treated with the surgical technique Biliopancreatic Derivation with Duodenal Switch (BPD DS) during the period from January 2003 to June 2013 in University Hospital Center Albacete (Centro Hospitalario Universitario de Albacete – CHUA).The meanage of the patients was41.8 years (21-60y), mean weight -139.13kg (100-193kg),height - 164.22cm (141-192cm), mean BodyMassIndex (BMI) – 51.91kg/m2 (41.62-75.06 kg/m2).A liver biopsy was performed intraoperatively in 124 patients.Nonalcoholic fatty liver disease (NAFLD) was found in 90.3% of patients with wide-ranging severity, and chronic hepatitis was found only in 1.4% of the patients. A statistically significant correlation between the severity of NAFLD and BMI was not established. Postoperatively, the elevation of liver enzymes GOT and GPT was most significant in the first 3 months but in the range of 50-100 UI. Chronologically, transaminase levels returned to normal, and in the 5th year after the operation, 4,9 % of patients had slightly elevated levels of GOT and GPT below 100 UI.

Abstract (Bulgarian)

Проведено бе ретро- и проспективно проучване по отношение на предоперативната чернодробна стеатоза и следоперативната чернодробна функция при пациенти с морбидно затлъстяване, третирани с хирургичната техника „билиопанкреатична деривация с дуоденално превключване – Biliopancreatic Derivation with Duodenal Switch (BPD DS)“ през периода януари 2003 – юни 2013 г. в Университетския болничен център на Албасете (Centro Hospitalario Universitario de Albacete - CHUA). Включени бяха 141 болни на средна възраст 41.8 години (21-60 г.), средно тегло 139.13 кг (100-193 кг), височина 163.22 см (141-192см) и среден Body Mass Index (BMI) 51.91 (41.62-75.06 кг/м²). Интраоперативно при 124 пациенти бе извършена чернодробна биопсия. Чернодробна стеатоза бе наблюдавана при 90.3% от пациентите в различна степен на тежест, а при 1.4% е открит неалкохолен стеатохепатит. Не се намира статистически значима връзка между тежестта на чернодробната стеатоза и големината на индекса за телесна маса. Следоперативно елевацията на чернодробните ензими GOT и GPT е била най-висока през първите 3 месеца, но в стойности 50-100 UI. С течение на времето, нивата на трансаминазите се нормализират и на 5-тата година 4,9 % отпациентите имат леко завишени нива на GOT и GPT до 100 UI.

Files

v87i3-3.pdf

Files (626.3 kB)

Name Size
md5:a97702f9f5bc37916056812051ac885b
626.3 kB Preview Download

Additional details

Additional titles

Translated title (Bulgarian)
Влияние на малабсорбтивна бариатрична хирургия върху чернодробната функция и предоперативната чернодробна стеатоза при пациенти с болестно затлъстяване

Identifiers

ISSN
3033-151X
URL
https://bgss.eu/index.php/surgery/article/view/7

Dates

Issued
2023-09-01

References

  • 1. Almeda-Valdes P, Altamirano-Barrera A, Uribe M, Méndez-Sánchez N. Metabolic Features of Alcoholic Liver Disease. Rev Recent Clin Trials. 2016 Aug 17;11(3):220–6.
  • 2. Sedletskii II, Berko OM, Zlotnikova EK. Functional-morphological changes in nonalcoholic fatty liver disease after bariatric operations. Grek Bull Surg. 2019;178(1):82–5.
  • 3. Wong VWS, Chitturi S, Wong GLH, Yu J, Chan HLY, Farrell GC. Pathogenesis and novel treatment options for nonalcoholic steatohepatitis. Lancet Gastroenterol Hepatol. 2016;1(1):56–67.
  • 4. Ahmed M. Management of Nonalcoholic Fatty Liver Disease (NAFLD). Nonalcoholic Fat Liver Dis - Mol Bases, Prev Treat [Internet]. 2018 Mar 21 [cited 2023 Apr 1]; Available from: http://www.intechopen.com/books/non-alcoholic-fatty-liverdisease-molecular-bases-prevention-and-treatment/management-of-nonalcoholic-fatty-liver-disease-nafld.
  • 5. Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: A future treatment by choice or by chance? J Obes. 2013;2013.
  • 6. Anstee QM, McPherson S, Day CP. How big a problem is nonalcoholic fatty liver disease? BMJ. 2011 Jul 23;343(7816).
  • 7. Liu Y-L, Day CP, Anstee QM. Can genetic influence in nonalcoholic fatty liver disease be ignored? Clin Dilemmas Nonalcoholic Fat Liver Dis. 2016 Feb 19;91–102.
  • 8. Angulo P. Nonalcoholic Fatty Liver Disease. N Engl J Med [Internet]. 2002 Apr 18 [cited 2023 Apr 1];346(16):1221–31. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMra011775.
  • 9. Luyckx FH, Desaive C, Thiry A, Dewé W, Scheen AJ, Gielen JE, et al. Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty. Int J Obes. 1998;22(3):222–6.
  • 10. Mathurin P. NAFLD, Obesity, and Bariatric Surgery. Nonalcoholic Fat Liver Dis A Pract Guid. 2013 Mar 8;149–56.
  • 11. Cholankeril G, Ahmed A. Alcoholic Liver Disease Replaces Hepatitis C Virus Infection as the Leading Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol. 2018 Aug 1;16(8):1356–8.
  • 12. Aguilar-Olivos NE, Almeda-Valdes P, Aguilar-Salinas CA, Uribe M, Méndez-Sánchez N. The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. Metabolism. 2016 Aug 1;65(8):1196–207.
  • 13. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019 Oct 1;71(4):793–801.
  • 14. Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes Metab. 2021 Mar 1;47(2).
  • 15. Stefan N, Cusi K. A global view of the interplay between nonalcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022 Apr 1;10(4):284–96.
  • 16. Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Reports. 2019 Oct 1;1(4):312–28.
  • 17. Sasaki A, Nitta H, Otsuka K, Umemura A, Baba S, Obuchi T, et al. Bariatric surgery and nonalcoholic fatty liver disease: Current and potential future treatments. Front Endocrinol (Lausanne). 2014;5(OCT).
  • 18. Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015 Aug 1;149(2):379–88.
  • 19. Laursen TL, Hagemann CA, Wei C, Kazankov K, Thomsen KL, Knop FK, et al. Bariatric surgery in patients with nonalcoholic fatty liver disease - From pathophysiology to clinical effects. World J Hepatol. 2019;11(2):138–249.
  • 20. Weiner RA. Surgical treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. Dig Dis. 2010 May;28(1):274–9.
  • 21. Keshishian A, Zahriya K, Willes EB. Duodenal switch has no detrimental effects on hepatic function and improves hepatic steatohepatitis after 6 months. Obes Surg. 2005 Nov;15(10):1418–23.
  • 22. Wolf AM, Beisiegel U. The effect of loss of excess weight on the metabolic risk factors after bariatric surgery in morbidly and super-obese patients. Obes Surg. 2007 Jul;17(7):910–9.
  • 23. Wolf AM, Busch B, Kuhlmann HW, Beisiegel U. Histological changes in the liver of morbidly obese patients: Correlation with metabolic parameters. Obes Surg. 2005 Feb;15(2):228–37.
  • 24. Tan CH, Al-Kalifah N, Ser KH, Lee YC, Chen JC, Lee WJ. Long-term effect of bariatric surgery on resolution of nonalcoholic steatohepatitis (NASH): An external validation and application of a clinical NASH score. Surg Obes Relat Dis. 2018 Oct 1;14(10):1600–6.
  • 25. Srivastava S, Younossi ZM. Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery. Hepatology. 2005 Aug;42(2):490–2.
  • 26. Baltasar A, Bou R, Bengochea M, Arlandis F, Escrivá C, Miró J, et al. Duodenal switch: An effective therapy for morbid obesity-Intermediate results. Obes Surg. 2001;11(1):54–8.
  • Baltasar A, Serra C, Pérez N, Bou R, Bengochea M. Clinical Hepatic Impairment after the Duodenal Switch. Obes Surg. 2004 Jan;14(1):77–83.